Table 5 Quality of life – post-HIFU outcome of QLQ-C30, QLQ-PR25 and IPSS-QoL questionnaires (n = 105). Data are shown as mean with standard deviation
QLQ - C30 | |
Global health status/QoL (QL2) | 69.4 (20.6) |
Functional scales | |
Physical functioning (PF2) | 86.2 (17.7) |
Role functioning (RF2) | 79.0 (29.9) |
Emotional functioning (EF) | 74.8 (23.5) |
Cognitive functioning (CF) | 83.3 (20.5) |
Social functioning (SF) | 74.8 (25.0) |
Symptom scales/items | |
Fatigue (FA) | 25.9 (24.8) |
Nausea and vomiting (NV) | 1.5 (6.7) |
Pain (PA) | 17.1 (27.8) |
Dyspnoea (DY) | 18.1 (26.6) |
Insomnia (SL) | 31.4 (31.4) |
Appetite loss (AP) | 4.8 (16.9) |
Constipation (CO) | 16.2 (27.0) |
Diarrhoea (DI) | 7.3 (19.6) |
Financial difficulties (FI) | 10.5 (23.3) |
QLQ - PR25 | |
Functional scales | |
Sexual activity(PRSAC)(n = 104) | 56.9 (28.1) |
Sexual functioning (PRSFU)(n = 71) | 49.6 (20.5) |
Symptom scales/items | |
Urinary symptoms (PRURI) | 28.3 (18.4) |
Urinary bother (PRAID) | 38.6 (35.6) |
Bowel symptoms (PRBOW) | 6.7 (11.2) |
ADT – treatments symptoms (PRHTR) | 16.4 (16.4) |
Quality - of - life; IPSS | |
Prä - HIFU | 2.1 (1.4) |
Post - HIFU | 2.0 (1.3) |